

# Identification of a *DAGLB* mutation in a Non-Chinese patient with Parkinson's disease.

Christelle Tesson<sup>1</sup>, PhD, Mohamed Sofiane Bouchetara<sup>2</sup>, MD, Mélanie Ferrien<sup>1</sup>, MSc, Suzanne Lesage<sup>1</sup>, PhD, Alexis Brice<sup>1,3</sup>, MD

<sup>1</sup> Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Paris, France

<sup>2</sup> Service de Neurologie, Etablissement hospitalo-universitaire, Oran, Algérie

<sup>3</sup> Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d'Investigation Clinique Neurosciences, DMU Neuroscience, Paris, France

Correspondence to: Prof. Alexis Brice, MD; Institut du Cerveau, ICM, Hôpital de la Salpêtrière, Paris, France

E-mail: alexis.brice@icm-institute.org | Tel.: +33 1 57 27 42 63

Characters Article title : 85/100

Characters Running title : 40/43

Word count :521/500

References : 4/7

Figure/Table : 1/1

Running title : *DAGLB* mutation in an Algerian PD patient.

Keywords: Autosomal recessive inheritance, *DAGLB*, Early-onset, Parkinson disease

Abbreviations: AR, autosomal recessive; CNV, copy number variation; EO, early-onset; PD, Parkinson's disease; WES, Whole Exome Sequencing

Liu and colleagues<sup>1</sup> recently reported that biallelic mutations in *DAGLB* are responsible for autosomal recessive early-onset Parkinson's disease (AR-EO-PD). They first identified a homozygous *DAGLB* splice site mutation in a consanguineous family with two affected siblings by combining homozygosity mapping and whole exome sequencing (WES). Through exome data mining in a large cohort of 1,741 unrelated PD cases, they identified three additional mutated index cases. All six patients were of Chinese origin and presented typical EO-PD ( $\leq 40$  years) with a good response to levodopa. No additional cases outside China have been reported so far.

To assess the causal role of pathogenic variants in *DAGLB* in our French cohort, we used data mining in the exomes of 55 families with AR-PD (n=88 cases), and 629 isolated EO-PD cases (Supplementary Data and Material). We identified a homozygous p.Pro357Leu missense variant in a single consanguineous PD case (Figure 1a). This mutation predicted to be deleterious by 13 out of 18 prediction softwares tested (Supplementary Table 1) affects a conserved amino acid localized in the catalytic domain of the protein, near the pathological p.Asp363Gly mutation described in the previous paper<sup>1</sup> (Figure 1b). It is predicted to destabilize the protein structure according to Dynamut2<sup>2</sup> (Figure 1c and 1d). All rare variants in the homozygous state identified in WES analysis of this patient are available in Supplementary Table 2.

The patient of Algerian origin was born to healthy first-cousins parents and reported no family history of PD. His family and social circumstances led him to stop his schooling at the age of 15. He presented at 30 years with bradykinesia and later developed postural instability and an akineto-rigid form of the disease, predominant on the right side, with an UPDRS III motor score of 25 and a Hoehn & Yahr score of 3 on "off" stage and of 2 under medication. Following 13 years of disease evolution, his akineto-rigid syndrome worsened with the presence of dysarthria, an UPDRS III score of 78 on "off" stage, and of 45 under medication

and a Hoehn & Yahr stage of 4 on the “off” stage which improved to 3 on medication. The patient did not show any frank cognitive impairment or hallucinations. At the last examination, he developed non-motor signs and symptoms, such as depression, constipation, urinary and sleep disturbances. Levodopa treatment led to significant improvement in clinical signs. The patient developed subsequently end-of-dose dyskinesias, motor fluctuations as well as dystonia in the “off” medication state. Brain MRI was normal (see Supplementary Table 3).

Thus, we identified a patient carrying the *DAGLB* p.Pro357Leu mutation localized nearby the previously published p.Asp363Gly<sup>1</sup> variant, reinforcing the fact that *DAGLB* is involved in EO-AR-PD. As the most frequent genes involved in AR-PD (*PRKN*<sup>3</sup>, *PINK1*<sup>4</sup>), the *DAGLB*-associated disease presents and evolves like typical PD. Since we screened a population of PD cases with either AR inheritance or EO-PD (< 50 years) and found a single patient among 683 index cases, we conclude that *DAGLB* is a very rare cause of AR-EO-PD. However, we demonstrate that mutations in *DAGLB* are not limited to the Chinese PD population but can also account for PD in North Africa.

## **Acknowledgment**

We thank the patients and their families. We thank the DNA and cell Bank .of the ICM for sample preparation. Part of this work was carried out on the iGenSeq and DAC core facilities of the ICM. We thank Dr. Poornima Menon for proofreading the text.

## **Authors' Roles**

- 1) Research project: A. Conception, B. Organization, C. Execution;
- 2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique;
- 3) Manuscript: A. Writing of the first draft, B. Review and Critique;
- 4) Clinical investigation.

Christelle Tesson : 1A, 1B, 1C, 3A

Mohamed Sofiane Bouchetara : 3B, 4

Suzanne Lesage: 1A, 1B, 3B

Alexis Brice: 1A, 1B, 3B, 4

All authors have read and agreed to the published version of the manuscript.

## **Funding Sources and Conflict of Interest:**

Part of this work was funded by grants from France Parkinson Association, Fondation de France (n° 00076353), la Fédération pour la Recherche sur le Cerveau (FRC), the program “Investissements d’avenir” (ANR-10-IAIHU-06). Authors report no conflicts of interest related to the paper

## **Financial Disclosures for the previous 12 months:**

Christelle Tesson was employed by Paris Brain Institute (ICM) during this work. Suzanne Lesage has received grants from Fondation de la Recherche Médicale (FRM, MND202004011718). Alexis Brice has received grants from Fondation Roger de Spoelberch and Greater Paris University Hospitals (APHP).


## **Ethical Compliance Statement**

Informed consent was obtained from all participants, and genetic studies were approved by local ethics committees (INSERM, CCPPRB du Groupe Hospitalier Pitié-Salpêtrière, Paris, France, N° 44814). We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.

## References

1. Liu Z, Yang N, Dong J, et al. Deficiency in endocannabinoid synthase DAGLB contributes to early onset Parkinsonism and murine nigral dopaminergic neuron dysfunction. *Nat Commun.* 2022;13:3490. doi:10.1038/s41467-022-31168-9
2. Rodrigues CHM, Pires DEV, Ascher DB. DynaMut2: Assessing changes in stability and flexibility upon single and multiple point missense mutations. *Protein Sci.* 2021;30(1):60-69. doi:10.1002/pro.3942
3. Lücking CB, Dürr A, Bonifati V, et al. Association between Early-Onset Parkinson's Disease and Mutations in the Parkin Gene. *New England Journal of Medicine.* 2000;342(21):1560-1567. doi:10.1056/NEJM200005253422103
4. Ibáñez P, Lesage S, Lohmann E, et al. Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. *Brain.* 2006;129(Pt 3):686-694. doi:10.1093/brain/awl005

## Figure



### Figure legends

**Fig. 1** Segregation and localization of the *DAGLB* p.Pro357Leu mutation. **a** Segregation of the *DAGLB* mutation in the SPD-2137 family. The patient is homozygous for the p.Pro357Leu mutation and his unaffected father is heterozygous for this mutation. **b** Localisation of the *DAGLB* mutation identified in our study nearby the p.Asp363Gly mutation identified in the lead article <sup>1</sup>, adapted from <sup>1</sup>. The catalytic domain is indicated in yellow. **c** Prediction of the wild-type *DAGLB* structure and amino acid interaction, obtained with DynaMut2 <sup>2</sup>. **d** Prediction of the mutated *DAGLB* structure due to the p.Pro357Leu mutation and amino acid interactions, obtained with DynaMut2 <sup>2</sup>. Predicted interactions are greatly modified compared to the wild type *DAGLB* ( $\Delta\Delta G^{\text{Stability}} = -0.49\text{kcal/mol}$ ). AO: age at onset, +: Wild type, M: mutated.

Created with BioRender.com

## **Supplementary Material and Methods**

### **Cohort description**

The cohort assembled by the French and Mediterranean Parkinson's Disease Genetics Study group (FMPD cohort) consisted of 683 index PD patients with available whole-exome sequencing (WES) data. Most of these patients present with early-onset PD. Mutations in the Parkinsonism-associated genes (Supplementary Table 4), were previously excluded using WES and multiplex ligation-dependent probe amplification<sup>1,2</sup>. Expansions in SCA2 and SCA17 were excluded using ExpansionHunter<sup>3,4</sup>.

This cohort included 716 patients with PD, 273 females and 443 males, from 683 families. 472 were from Europe, 102 from North Africa, 7 from South Africa, 1 from Asia and 134 of unknown origin. Among them, 55 families with at least two affected siblings (n = 88 patients) were compatible with AR PD, including 13 families (n = 20 patients) with parental consanguinity. 628 patients were isolated cases, including 61 with consanguinity. WES data were available for all index cases, 33 additional affected members and 53 unaffected relatives. The mean age at onset of motor signs was 35.7 years (range: 6 to 77 years).

Informed consent was obtained from all participants, and the genetic studies were approved by local ethics committees (INSERM, CCPPRB du Groupe Hospitalier Pitié-Salpêtrière, Paris, France).

### **Exome sequencing and analyses**

WES in the FMPD cohort was performed at the ICM IGenSeq core facility, Integragen service (Evry, France) or through the NIH facility. Exons were captured using the SureSelect Human All Exon Kits Version 2 Agilent, the Human All Exon V4+UTRs – 70 Mb Agilent, the Human All Exon Agilent, the Roche V.3, Medexome or the Twist Refseq kit, followed by

a massively parallel sequencing on the HiSEQ 2000, or the NextSeq500 or NovaSeq system (Illumina). The mean coverage was 104.9X (range 51.1-225.8X) and 25, 30, 50-fold mean sequencing depth was achieved across 84.6% (range 79.5-90.4%), 86% (range 58.4-95.5%) and 81.4% (range 57-97.3%) of targeted regions, respectively. *DAGLB* specific coverage was analyzed using an in house script from the DAC core facility, based on transcript ENST00000297056 for exon and 5' and 3'UnTranslated Regions (UTR) localization. The mean coverage was 67.5X (range 12.9-209.2X), an example of the *DAGLB* coverage is shown on Supplementary Figure 1. Read alignment and variant calling were done using an in-house pipeline. Briefly, FastQC was used to check the quality of the reads and low-quality reads were removed using Trimmomatic. Sequencing data were then aligned to the human reference genome hg19 using the bwa suite<sup>36</sup> and variant calling was performed using GATK HaplotypeCaller<sup>5</sup> or Dragen (Illumina).

For 362 index cases, 25 additional patients and 38 unaffected relatives we were able to detect CNVs based on WES data. Briefly, the DRAGENTM DNA pipeline v3.8.4 (Illumina) was used to align the reads to the human hg19 reference genome, mark the PCR duplicates and perform the calling of the Copy Number Variants using the panel of normals approach. Each sample's depth of coverage being first corrected for the GC bias and then normalized against the depth of all the unrelated samples in the same sequencing batch. Only the events passing the default filters were considered for analysis and annotated with AnnotSV v3.1.1<sup>6</sup>. For the other individuals of the cohort (n=344), it was not possible due to the fact that too few individuals were sequenced together in the same batch.

Variants in *DAGLB* were extracted using the graphical interface developed by the DAC core facility (<https://quby.icm-institute.org/app/dejavu>) and annotated with a in house R script. We filtered all homozygous or double heterozygous variants in *DAGLB* that possibly affected the cDNA or localized in the splice site region (-8 +11bp from exon/intron junction) and with a



MAF<1% in the gnomAD public database. All variants identified in our cohort, including heterozygous variants, are listed in Supplementary Table 5.

For patient SPD-2137-1, WES was analyzed using VarFT<sup>7</sup> software. We filtered all homozygous variants that possibly affected the cDNA or localized in the splice site region (-8 +11bp from exon/intron junction), with a MAF<1% in the gnomAD public database and localized in region of loss of heterozygosity (Supplementary Table 6).

### **Detection of run of homozygosity**

For patient SPD-2137 1 homozygosity mapping was performed using Automap<sup>8</sup> from the VCF file of WES data. Region of homozygosity are available on the Supplementary Table 3.

### **Variant segregation**

For individuals from family SPD-2137 and individuals listed in Supplementary Table 5, the presence of the variant was checked on the bam file using IGV software (<https://software.broadinstitute.org/software/igv/>).

### **3D structural modelling of DAGLB and predicted impact of the mutation**

DAGLB 3D protein structure was downloaded from Uniprot using the structure predict by AlphaFold<sup>9</sup> (Q8NCG7). Then, the impact of the mutation was predict using DynaMut2<sup>10</sup> and PremPS<sup>11</sup>

**Supplementary Table 1.** Pathogenicity score and prediction for the chr7:g.6464453G>A variant of DAGLB obtained with dbNSFP4.3a<sup>12-14</sup>

gene_id	DAGLB
genomic	chr7:g.6464453G>A
hgvs_c	c.1070C>T
hgvs_p	p.Pro357Leu
Eigen-raw_coding	0.84
Eigen-phred_coding	9.66
SIFT4G_score	0.00
SIFT4G_pred	Damaging
Polyphen2_HDIV_score	1.0
Polyphen2_HDIV_pred	probably Damaging
MutationTaster_score	1.00
MutationTaster_pred	Disease_causing
MutationAssessor_score	3.175
MutationAssessor_pred	Medium
LRT_score	0.00
LRT_pred	Deleterious
CADD_raw	3.97
CADD_phred	26.8
MetaLR_score	0.42
MetaLR_pred	Tolerated
M-CAP_score	0.08
M-CAP_pred	Damaging
MutPred_AAchange	P357L
MutPred_score	0.70
MutPred_Top5features	Loss of ubiquitination at K352 (P = 0.0787)
REVEL_score	0.66
PROVEAN_score	-8.68
PROVEAN_pred	Damaging
VEST4_score	0.98
MetaSVM_score	-0.10
MetaSVM_pred	Tolerated
PrimateAI_score	0.72
PrimateAI_pred	Tolerated
MVP_score	0.87
DEOGEN2_score	0.54
DEOGEN2_pred	Damaging
ClinPred_score	0.98
ClinPred_pred	Deleterious

.Predicted deleterious score are indicated in Yellow, predicted tolerated score are indicated in green.

**Supplementary Table 2.** Coding or splice site variants, absent from GnomAD in the homozygous state, identified in the WES analyses of patient SPD-2137-1

Nature of the variants	hg19 genomic position	gene_id	hgvs_c	hgvs_p	Htz GnomAD	Hmz GnomAD	Chr GnomAD
missense_variant	chr1:g.1961503C>T	GABRD	c.1141C>T	p.Arg381Cys	5	0	276182
synonymous_variant	chr6:g.33643510C>T	ITPR3	c.3159C>T	p.Arg1053Arg	103	0	280076
missense_variant	chr6:g.33996029C>A	GRM4	c.2557G>T	p.Val853Leu	15	0	251320
missense_variant	chr6:g.42072819A>G	C6orf132	c.2831T>C	p.Val944Ala	21	0	173072
missense_variant	chr6:g.43251078C>T	TTBK1	c.2600C>T	p.Pro867Leu	23	0	237208
synonymous_variant	chr7:g.4839063C>T	RADIL	c.3174G>A	p.Ala1058Ala	110	0	280618
missense_variant	chr7:g.6464453G>A	DAGLB	c.1070C>T	p.Pro357Leu	5	0	282848
missense_variant	chr7:g.149489813C>T	SSPO	c.5869C>T	p.Arg1957Cys	227	0	213992
missense_variant	chr16:g.10729739T>G	TEKT5	c.1123A>C	p.Met375Leu	49	0	282730
stop_gained&splice_region_variant	chr16:g.57448995C>T	CCL17	c.73C>T	p.Arg25*	8	0	282676
missense_variant&splice_region_variant	chr16:g.57998447G>C	CNGB1	c.161C>G	p.Pro54Arg	1	0	249466
missense_variant	chr16:g.58043902G>A	USB1	c.335G>A	p.Arg112Gln	37	0	282838
missense_variant	chr19:g.48305050C>A	TPRX1	c.1218G>T	p.Arg406Ser	28	0	281736
missense_variant	chr19:g.49565052C>T	NTF4	c.203G>A	p.Arg68Gln	197	0	187424
missense_variant	chr19:g.49655273C>T	HRC	c.2014G>A	p.Val672Ile	483	0	282296
missense_variant	chr19:g.50755969A>G	MYH14	c.1904A>G	p.His635Arg	NA	NA	NA
missense_variant	chr19:g.56538791G>A	NLRP5	c.1192G>A	p.Val398Ile	11	0	279368
missense_variant	chr19:g.56599855G>C	ZNF787	c.686C>G	p.Ala229Gly	0	0	22454
missense_variant	chr19:g.57641219T>G	USP29	c.1176T>G	p.Asn392Lys	9	0	250986
missense_variant	chr19:g.57642033G>A	USP29	c.1990G>A	p.Glu664Lys	9	0	251082
frameshift	chr6:g.27861345_27861346delAG	H2BC17	c.109_110del	p.(Ser37Leufs*32)	4	0	251452

This table was created with the R package myvariant 1.20.0<sup>15</sup>.

**Supplementary Table 3.** Clinical data of the patient SPD-2137-1 and the patients of the lead article. Adapted from Liu et al, 2022<sup>16</sup>

	Liu et al, 2022							Our case
	Family 1 II-3	Family 1 II-4	Family 2 II-4	Family 3 II-1	Family 3 II-2	Family 4 II-1	SPD-2137-1	
<b>Mutation</b>	c.1821-2A>G	c.1821-2A>G	c.1088A>G p.Asp363Gly	g.chr7:6,486,383-6,489,136 del	g.chr7:6,486,383-6,489,136 del	c.469dupC p.Leu158Serfs*17	c.1070C>T p.Pro357Leu	
<b>Age at onset (years)</b>	<40	<40	<40	<40	<40	<40	30	
<b>Age at examination (year)</b>	NA	NA	NA	NA	NA	NA	43	
<b>Symptoms at onset</b>	Resting tremor	Resting tremor	Bradykinesia	Resting tremor	Resting tremor	Bradykinesia	Bradykinesia	
<b>Asymmetry at onset</b>	+	+	+	+	+	+	+	
<b>Hoehn-Yahr stage (Off/On)</b>	IV/II	IV/II	IV/II	III/II	V/III	III/II	IV/III	
<b>Motor symptom</b>								
Bradykinesia	+	+	+	+	+	+	+	
Resting tremor	+	+	+	+	+	+	+	
Rigidity	+	+	+	+	+	+	+	
Postural instability	+	+	+	+	+	+	+	
Hypomimia	+	+	+	+	+	+	+	
UPDRS III (Off/On)	56/37	74/40	76/33	52/30	76/58	50/28	78/45	
<b>Nonmotor symptom</b>								
Depression	+	+	+	+	+	+	+	
Urinary urgency	+	+	+	-	+	+	+	
Constipation	-	+	+	-	+	+	+	
Cognitive decline	-	-	-	+	-	-	-	
Hallucination	+	-	-	-	-	-	-	
Sleep disturbance	+	+	+	+	+	+	+	
Freezing gait	+	+	+	+	+	+	+	
RBD	-	+	+	+	-	-	-	
<b>Response to levodopa</b>	+	+	+	+	+	+	+	
<b>Complications with treatment</b>								

Wearing off	+	+	+	+	+	+	+
On-off phenomenon	+	+	+	+	+	+	+
Dyskinesia	+	+	+	-	-	+	+
Surgical therapies	NA	NA	+*	NA	+#	NA	NA
<b>Brain MRI</b>	-	-	-	-	-	-	Normal
<b>Brain 11C-CFT PET</b>	NA	NA	Abnormal*	NA	NA	NA	NA

+ = Present; - = Absent; NA=Not performed

\* Deep brain stimulation

# Posteroventral pallidotomy

\*Severe striatal uptake deficit, particularly at putamen level, as seen in Parkinson's disease

MRI=magnetic resonance imaging; PET=positron emission tomography; CFT=C-2β-carbomethoxy-3β-(4-fluorophenyl) tropane

**Supplementary Table 4.** Known genes or genes related to Parkinson's disease/Parkinsonism excluded from our cohort

<b>Gene</b>	<b>Transmission</b>	<b>Designation</b>	<b>NM number</b>
<i>SNCA</i>	AD	PARK- <i>SNCA</i>	NM_000345.3
<i>PRKN</i>	AR	PARK- <i>Parkin</i>	NM_004562.2
<i>PINK1</i>	AR	PARK- <i>PINK1</i>	NM_032409.2
<i>PARK7</i>	AR	PARK- <i>DJI</i>	NM_007262.4
<i>LRRK2</i>	AD	PARK- <i>LRRK2</i>	NM_198578.3
<i>ATP13A2</i>	AR	MxMD- <i>ATP13A2</i>	NM_022089.2
<i>UCHL1</i>	AD	HSP/ATX- <i>UCHL1</i>	NM_004181.4
<i>GIGYF2</i>	AD	Risk Factor	NM_001103147.1
<i>HTR2A</i>	AD	Risk Factor	NM_000621.4
<i>PLA2G6</i>	AR	MxMD- <i>PLA2G6</i>	NM_003560.2
<i>FBXO7</i>	AR	PARK- <i>FBXO7</i>	NM_012179.3
<i>VPS35</i>	AD	PARK- <i>VPS35</i>	NM_018206.5
<i>EIF4G1</i>	AD	Risk Factor	NM_182917.4
<i>DNAJC6</i>	AR	PARK- <i>DNAJC6</i>	NM_001256864.1
<i>SYNJ1</i>	AR	PARK- <i>SYNJ1</i>	NM_003895.3
<i>SLC6A3</i>	AR	DYT/PARK- <i>SLC6A3</i>	NM_001044.4
<i>VPS13C</i>	AR	PARK- <i>VPS13C</i>	NM_020821.2
<i>TMEM230</i>	AD	Risk Factor	NM_001009923.1
<i>RIC3</i>	AD		NM_024557.4
<i>CHCHD2</i>	AD	PARK- <i>CHCHD2</i>	NM_001320327.1
<i>DNAJC13</i>	AD	Risk Factor	NM_001329126.1
<i>GBA1</i>	Mu/AD	PARK- <i>GBA</i>	NM_001005741.2
<i>ADH1C</i>	Mu/AD		NM_000669.4
<i>TBP</i>	Mu/AD	SCA- <i>TBP</i>	NM_003194.4
<i>ATXN2</i>	Mu/AD	SCA- <i>ATXN2</i>	NM_002973.3
<i>MAPT</i>	Mu/AD		NM_001123066.3
<i>GCHI</i>	AD/AR	DYT/PARK- <i>GCHI</i>	NM_001024024.1
<i>DCTN1</i>	AD/AR	PARK- <i>DCTN1</i>	NM_004082.4
<i>PANK2</i>	AR	DYT- <i>PANK2</i> - (NBIA)	NM_153638.2
<i>POLG</i>	AR/AD	MxMD- <i>POLG</i>	NM_002693.2
<i>SPG11</i>	AR	SPG- <i>KIAA1840</i>	NM_025137.3
<i>TH</i>	AR	DYT/PARK- <i>TH</i>	NM_199292.2
<i>ADORA1</i>	AR		NM_000674.2
<i>RAB39B</i>	XLR	PARK- <i>RAB39B</i>	NM_171998.3
<i>TNK2</i>	AD		NM_001010938.1
<i>PODXL</i>	AD		NM_001018111.2
<i>TNR</i>	AD		NM_003285.2
<i>PTRHD1</i>	AR		NM_001013663.2

AD, autosomal dominant; AR, autosomal recessive, Mu, Multifactorial according to OMIM (<https://www.omim.org>). Designation were obtained using recommendation<sup>17-20</sup>.

**Supplementary Table 5.** Rare *DAGLB* variants identified in our cohort of 716 patients with PD from 683 families

genomic	hgvs_c	hgvs_p	Ind	Zygoty	GnomAD Htz/Hmz/Chr	Pathogenicity	ACMG classificaiton	Index cases	Sex	Statut	Ethnicity	AAO	Inheritance	Consanguinity
chr7:g.6449476C>T	c.2011G>A	p.Val671Met	SPD-755-16	htz	12/0/281876	3/17	VUS	Yes	Male	Affected	CAU	45	Isolated case	No
chr7:g.6449816G>C	c.1765C>G	p.Pro589Ala	6619NG003901	htz	44/0/260808	3/18	VUS	Yes	Male	Affected	NA	32	Isolated case	No
chr7:g.6449930C>T	c.1651G>A	p.Asp551Asn	G1801	htz	22/0/282008	0/17	VUS	Yes	Male	Affected	CAU	45	Isolated case	No
chr7:g.6449947G>T	c.1634C>A	p.Thr545Lys	SPD-363-1	htz	271/0/282344	8/17	VUS	Yes	Male	Affected	CAU	41	Isolated case	No
chr7:g.6461357C>A	c.1218+1G>T	p.( ?)	16NG001469	htz	Absent	3/3	VUS	Yes	Male	Affected	NA	20	Isolated case	Yes
chr7:g.6464453G>A	c.1070C>T	p.Pro357Leu	SPD-2137-2	htz	5/0/282848	13/18	VUS	No	Male	Not_Affected	NoAf			No
chr7:g.6464453G>A	c.1070C>T	p.Pro357Leu	SPD-2137-1	hmz	5/0/282848	13/18	VUS	Yes	Male	Affected	NoAf	30	Isolated case	Yes
chr7:g.6472577A>G	c.692T>C	p.Val231Ala	PD-TU-28	htz	42/0/281998	12/17	VUS	Yes	Female	Affected	NoAf	40	Isolated case	No
chr7:g.6472577A>G	c.692T>C	p.Val231Ala	SPD-492-11	htz	42/0/281998	12/17	VUS	Yes	Male	Affected	NoAf	19	Isolated case	Yes
chr7:g.6472577A>G	c.692T>C	p.Val231Ala	SPD-1547-1	htz	42/0/281998	12/17	VUS	Yes	Male	Affected	NA	34	Isolated case	Yes
chr7:g.6472577A>G	c.692T>C	p.Val231Ala	SPD-2166-7	htz	42/0/281998	12/17	VUS	Yes	Male	Affected	NoAf	26	Isolated case	Yes
chr7:g.6472577A>G	c.692T>C	p.Val231Ala	SPD-2158-6	htz	42/0/281998	12/17	VUS	Yes	Male	Affected	NoAf	45	Isolated case	No
chr7:g.6474561del	c.510del	p.(Ser171Alafs*105)	SPD-1597-1	htz	Absent	NA	VUS	Yes	Female	Affected	NA	27	Isolated case	ND
chr7:g.6476030T>C	c.382A>G	p.Thr128Ala	16NG003029	htz	Absent	1/18	VUS	Yes	Male	Affected	NA	40	Isolated case	No
chr7:g.6476140C>G	c.272G>C	p.Arg91Pro	17NG001059	htz	Absent	16/18	VUS	Yes	Male	Affected	NA	49	Isolated case	No
chr7:g.6476161G>C	c.251C>G	p.Thr84Arg	6619NG003284	htz	712/3/282162	9/17	VUS	Yes	Female	Affected	NA	23	Isolated case	No

This table was created with the R package myvariant 1.20.0<sup>15</sup>. ACMG<sup>22</sup> nomenclature was obtained using Franklin by genoox (<https://franklin.genoox.com/clinical-db/home>), VUS : Variant of unknown significance, CAU : Caucasian origin, NoAf : North African origin, NA : Information not available.

**Supplementary Table 6.** List of homozygosity regions for patient SPD-2137-1 detected with Automap<sup>8</sup>

#Chr	Begin	End	Size(Mb)	Nb_variant s	Percentage_homozygosit y
chr1	69270	3342804	3.27	114	94.74
chr1	193051685	199717218	6.67	43	93.02
chr6	18264210	31238983	12.97	231	97.4
chr6	31324144	32489672	1.17	113	93.81
chr6	32551961	45320548	12.77	228	96.93
chr7 *	2946461	11075263	8.13	82	93.9
chr7	149191568	150439500	1.25	33	90.91
chr11	45230862	52516144	7.29	75	93.33
chr12	50040811	51393116	1.35	34	88.24
chr12	123087442	124246910	1.16	33	90.91
chr13	103473497	113665848	10.19	96	96.87
chr14	100772102	103799695	3.03	37	89.19
chr16	5140541	15091589	9.95	122	98.36
chr16	56504724	59757683	3.25	66	98.48
chr18	4197503	11610332	7.41	55	98.18
chr18	11610629	28681903	17.07	84	96.43
chr19	45515345	52130488	6.62	288	99.31
chr19	54849481	59080698	4.23	257	100
chr20	59485627	62737568	3.25	134	100
chr22	47132809	51183255	4.05	80	98.75

Default settings used:

## INFO: 125.08 Mb are in Homozygous Regions (autosomal chromosomes)

## AutoMap v1.0 used for analysis

## Variant filtering parameters used: DP=8, percallow=.25, percalhigh=.75, binomial=.000001, maxgap=10

## Other parameters used: window=7, windowthres=5, minsize=1, minvar=25, minperc=88, chrX=No, extend=1

\* *DAGLB* localization



**Supplementary Figure 1.** Example of DAGLB coverage for one individuals of our cohort that shown that all exons are well covered. The uncover region is limited to the end of the 3'UTR.




Figure obtained with the package R Gviz<sup>21</sup>.

## 1 Supplementary references

- 2 1. Lesage S, Lunati A, Houot M, et al. Characterization of Recessive Parkinson Disease in a  
3 Large Multicenter Study. *Ann Neurol.* 2020;88(4):843-850. doi:10.1002/ana.25787
- 4 2. Lesage S, Houot M, Mangone G, et al. Genetic and Phenotypic Basis of Autosomal  
5 Dominant Parkinson's Disease in a Large Multi-Center Cohort. *Front Neurol.*  
6 2020;11:682. doi:10.3389/fneur.2020.00682
- 7 3. Dolzhenko E, Deshpande V, Schlesinger F, et al. ExpansionHunter: a sequence-graph-  
8 based tool to analyze variation in short tandem repeat regions. *Bioinformatics.*  
9 2019;35(22):4754-4756. doi:10.1093/bioinformatics/btz431
- 10 4. Casse F, Courtin T, Tesson C, et al. Detection of ATXN2 Expansions in an Exome  
11 Dataset: An Underdiagnosed Cause of Parkinsonism. *Mov Disord Clin Pract.*  
12 2023;10(4):664-669. doi:10.1002/mdc3.13699
- 13 5. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce  
14 framework for analyzing next-generation DNA sequencing data. *Genome Res.*  
15 2010;20(9):1297-1303. doi:10.1101/gr.107524.110
- 16 6. Geoffroy V, Herenger Y, Kress A, et al. AnnotSV: an integrated tool for structural  
17 variations annotation. *Bioinformatics.* 2018;34(20):3572-3574.  
18 doi:10.1093/bioinformatics/bty304
- 19 7. Desvignes JP, Bartoli M, Delague V, et al. VarAFT: a variant annotation and filtration  
20 system for human next generation sequencing data. *Nucleic Acids Research.*  
21 2018;46(W1):W545-W553. doi:10.1093/nar/gky471
- 22 8. Quinodoz M, Peter VG, Bedoni N, et al. AutoMap is a high performance homozygosity  
23 mapping tool using next-generation sequencing data. *Nat Commun.* 2021;12:518.  
24 doi:10.1038/s41467-020-20584-4
- 25 9. Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with  
26 AlphaFold. *Nature.* 2021;596(7873):583-589. doi:10.1038/s41586-021-03819-2
- 27 10. Rodrigues CHM, Pires DEV, Ascher DB. DynaMut2: Assessing changes in stability  
28 and flexibility upon single and multiple point missense mutations. *Protein Sci.*  
29 2021;30(1):60-69. doi:10.1002/pro.3942
- 30 11. PremPS: Predicting the impact of missense mutations on protein stability - PubMed.  
31 Accessed February 2, 2023. [https://pubmed-ncbi-nlm-nih-](https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/33378330/)  
32 [gov.proxy.insermbiblio.inist.fr/33378330/](https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/33378330/)
- 33 12. Liu X, Jian X, Boerwinkle E. dbNSFP: a lightweight database of human  
34 nonsynonymous SNPs and their functional predictions. *Hum Mutat.* 2011;32(8):894-899.  
35 doi:10.1002/humu.21517
- 36 13. Liu X, Li C, Mou C, Dong Y, Tu Y. dbNSFP v4: a comprehensive database of  
37 transcript-specific functional predictions and annotations for human nonsynonymous and  
38 splice-site SNVs. *Genome Med.* 2020;12(1):103. doi:10.1186/s13073-020-00803-9

- 39 14. Dong C, Wei P, Jian X, et al. Comparison and integration of deleteriousness  
40 prediction methods for nonsynonymous SNVs in whole exome sequencing studies. *Human*  
41 *Molecular Genetics*. 2015;24(8):2125-2137. doi:10.1093/hmg/ddu733
- 42 15. Adam M. myvariant: Accesses MyVariant.info variant query and annotation services.  
43 R package version 1.20.0.
- 44 16. Liu Z, Yang N, Dong J, et al. Deficiency in endocannabinoid synthase DAGLB  
45 contributes to early onset Parkinsonism and murine nigral dopaminergic neuron  
46 dysfunction. *Nat Commun*. 2022;13:3490. doi:10.1038/s41467-022-31168-9
- 47 17. van der Veen S, Zutt R, Klein C, et al. Nomenclature of Genetically Determined  
48 Myoclonus Syndromes: Recommendations of the International Parkinson and Movement  
49 Disorder Society Task Force. *Movement Disorders*. 2019;34(11):1602-1613.  
50 doi:10.1002/mds.27828
- 51 18. Lange LM, Gonzalez-Latapi P, Rajalingam R, et al. Nomenclature of Genetic  
52 Movement Disorders: Recommendations of the International Parkinson and Movement  
53 Disorder Society Task Force – An Update. *Movement Disorders*. 2022;37(5):905-935.  
54 doi:10.1002/mds.28982
- 55 19. Marras C, Lang A, van de Warrenburg BP, et al. Nomenclature of genetic movement  
56 disorders: Recommendations of the international Parkinson and movement disorder  
57 society task force. *Movement Disorders*. 2016;31(4):436-457. doi:10.1002/mds.26527
- 58 20. Rossi M, Anheim M, Durr A, et al. The genetic nomenclature of recessive cerebellar  
59 ataxias. *Movement Disorders*. 2018;33(7):1056-1076. doi:10.1002/mds.27415
- 60 21. Hahne F, Ivanek R. Visualizing Genomic Data Using Gviz and Bioconductor.  
61 *Methods Mol Biol*. 2016;1418:335-351. doi:10.1007/978-1-4939-3578-9\_16
- 62 22. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of  
63 sequence variants: a joint consensus recommendation of the American College of Medical  
64 Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*.  
65 2015;17(5):405-424. doi:10.1038/gim.2015.30